Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage points of return.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories. Abbott leaned on consumer-facing devices and diagnostics that sit inside pharmacies and homes. Danaher leaned on bioprocessing tools and lab equipment sold to drugmakers. One business feels recession resistant. The other depends on capital spending decisions inside biotech.
FreeStyle Libre Carries Abbott. Cepheid Drags Danaher.
Abbott’s Medical Devices segment hit $5.539 billion, up 13.2%, with FreeStyle Libre continuous glucose monitors alone bringing in $2.08 billion. That is a device sold to millions of everyday diabetics, and CEO Robert Ford told investors the addressable market sits at “between 70 million and 80 million people” globally against roughly 10 to 12 million users today. Cologuard, absorbed through the $21 billion Exact Sciences deal closed March 23, grew mid-teens.
Danaher’s picture is messier. Diagnostics core sales fell 4.0% as Cepheid respiratory revenue dropped roughly 25% year over year on a soft flu season. Bioprocessing equipment declined modestly, though CEO Rainer Blair pointed to “orders growth of more than 30%, marking the first quarter of year-over-year equipment order growth in nearly 2 years.” Encouraging, but customer wallets stay tight.
Consumer Cash Flow Versus Capital Equipment Cycles
| Lens | Abbott | Danaher |
| Core Bet | Consumer medical devices, CGM, cancer screening | Bioprocessing tools, lab instruments, diagnostics |
| Growth Engine | FreeStyle Libre, Cologuard, Electrophysiology | Cytiva bioprocessing consumables |
| Main Vulnerability | Nutrition volume, FX, tariffs | Biotech capex cycle, respiratory seasonality |
Abbott’s growth reads like a consumer staples business dressed as healthcare. Rhythm Management posted its third consecutive quarter of double-digit growth, and Ford framed Cologuard’s edge against a “fixed amount of colonoscopy capacity”. Danaher’s fortunes depend on when biotech customers greenlight new bioreactor lines. Nutrition remains Abbott’s soft spot at -6.0%, which I would not ignore.
The Next Test Is Biotech Capex
Danaher raised its full-year adjusted EPS band to $8.35 to $8.55 and guided Q2 adjusted operating margin near 26.5%. The Masimo acquisition adds patient monitoring, but integration risk is real. Abbott guided full-year comparable sales growth of 6.5% to 7.5% and Q2 adjusted EPS of $1.25 to $1.31. Polymarket traders currently assign a 32% probability that Abbott’s Q2 comparable sales growth lands in the 8% to 10% range.
Why I Lean Toward Abbott Right Now
I want the business that gets paid whether or not biotech venture funding thaws. Abbott sells sensors, screening tests, and cardiac devices to patients and insurers, and it just paid its 409th consecutive quarterly dividend in a 54th consecutive year of increases. Shares are down 26.76% year to date, a notable drawdown against the CGM runway.
Danaher fits a different investor. For investors who believe the bioprocessing order rebound is real and durable, DHR trades at $190.48, offering leverage to that recovery. The consumer cash flow engine looks more durable today, with Danaher worth revisiting once brownfield projects convert into greenfield builds.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
